Effects of experimentally induced respiratory disease on the pharmacokinetics and tissue residues of tulathromycin in meat goats.

Abstract

Tulathromycin is a macrolide antibiotic commonly used for the treatment of respiratory disease in food animal species including goats. Recent research in pigs has suggested that the presence of disease could alter the pharmacokinetics of tulathromycin in animals with respiratory disease. The objectives of this study were (a) compare the plasma pharmacokinetics of tulathromycin in healthy goats as well as goats with an induced respiratory disease; and (b) to compare the tissue residue concentrations of tulathromycin marker in both groups. For this trial, disease was induced with Pasteurella multocida. Following disease induction, tulathromycin was administered. Samples of plasma were collected at various time points up to 312hr posttreatment, when study animals were euthanized and tissue samples were collected. For PK parameters in plasma, Vz (control: 28.7±11.9ml/kg; experimental: 57.8±26.6ml/kg) was significantly higher (p=0.0454) in the experimental group than the control group, and nonsignificant differences were noted in other parameters. Among time points significantly lower plasma concentrations were noted in the experimental group at 168hr (p=0.023), 216hr (p=0.036), 264hr (p=0.0017), 288hr (p=0.0433), and 312hr (p=0.0486). None of the goats had tissue residues above the US bovine limit of 5µg/g at the end of the study. No differences were observed between muscle, liver, or fat concentrations. A significantly lower concentration (p=0.0095) was noted in the kidneys of experimental goats when compared to the control group. These results suggest that the effect of respiratory disease on the pharmacokinetics and tissue residues appear minimal after experimental P.multocida infection, however as evidenced by the disparity in Cmax , significant differences in plasma concentrations at terminal time points, as well as the differences in kidney concentrations, there is the potential for alterations in diseased versus clinical animals.